secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIO-TECHNE Corp (TECH)
CIK:        0000842023
Form:       8-K
Filed at:   2023-08-08T23:59:59+00:00
Accession:  0001558370-23-013727
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bio-Techne Q4 revenue up 5% to $301.3M; GAAP EPS $0.47 vs $0.38, adjusted EPS $0.55 vs $0.51
--------------------------------------------------------------------------------

- Full-year organic revenue grew 5% to $1.1B; GAAP EPS $1.76, adjusted EPS $1.99.
- Diagnostics & Genomics segment organic growth 10% in Q4; full-year 8%.
- ExoDx prostate test revenue surged 68% in Q4; GMP proteins up 58%.
- Acquired Lunaphore (COMET spatial biology platform) – no deal value disclosed.
- Quarterly dividend declared $0.08/share, payable Sept 1, record Aug 18.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/842023/000155837023013727/0001558370-23-013727-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/842023/000155837023013727/tmb-20230808x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-013727

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer